Automated Insulin Delivery Systems Market is Segmented By Device Type (Reusable Insulin Pens, Disposable Insulin Pens), By Insulin Pumps (External/ Tethered Pumps, Implanted Insulin pump (IIP), Patch Pumps, Closed-loop insulin pump, Others), By Pen Needles (Standard Pen Needles, Safety Pen Needles, Others), By End-User (Hospitals, Clinics, Homecare, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023- 2030.
Automated Insulin Delivery Systems Market is expected to reach at a CAGR of 9.7% during the forecast period (2023- 2030). Automated insulin delivery systems are automated (or semi-automated) systems that enable patients with diabetes, mainly type 1, to control their blood glucose levels by automatically adjusting insulin delivery.
Automated Insulin Delivery Systems Market
|
Metrics |
Details |
|
Market CAGR |
9.7% |
|
Segments Covered |
By Device Type, By Insulin Pumps, By Pen Needles, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Market Dynamics
Advancement in next-generation automatic insulin delivery systems is expected to drive market growth.
RocketAP, a brand-new automated insulin delivery (AID) algorithm, helped adolescents with type 1 diabetes stay more time in range after meals, even when they didn't take mealtime (bolus) insulin, according to tiny but interesting research. RocketAP is similar to Control-IQ, but it has a unique system feature that can detect unscheduled meals and provide bolus insulin fast to minimize high blood sugar levels afterward (hyperglycemia). Moreover, a study was conducted where Tandem insulin pumps and Dexcom G6 CGMs were used, and the results were impressive and could indicate the first steps toward a fully closed-loop algorithm. Thus, from the above statements, the market is expected to boost in the forecast period.
The drawbacks associated with automated insulin delivery systems are expected to hamper market growth.
Infusion sets that are kinked or unintentionally torn out, malfunctioning pumps, dead batteries, and infusion site adhesion concerns are major insulin pump issues. There are also budget pressures when it comes to reimbursement. Pumps, CGM sensors, and AID systems are all expensive, and most people can only afford to use them if they have insurance. Even DIY systems need customers to pay a yearly charge for a software development license and the upfront price of any hardware needed to link their pump and algorithm. There is a risk of skin infection or allergic reaction by infusion pumps. Thus, the market is expected to get hampered in the forecast period from the above statements.
Industry Analysis.
COVID-19 Impact Analysis
The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on the automated insulin delivery systems market. In hospitalized patients with COVID-19, type 1 and type 2 diabetes are associated with an increased risk of death, with a larger number of deaths in people with type 1 and type 2 diabetes living in the most deprived neighborhoods than those living in the least deprived districts. Moreover, hyperglycemia and obesity are linked to COVID-19 mortality in persons with diabetes. Secondly, SARS-CoV-2 can, directly and indirectly, impact glucose metabolism by triggering beta cell death and raising insulin resistance. Self-management of type 1 diabetes (T1D) can be difficult, requiring numerous daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), all of which are guided by glucose self-monitoring.
Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Segment Analysis
Reusable Insulin Pens segment is expected to hold the largest market share in automated insulin delivery systems market
The reusable insulin pens segment is expected to dominate in 2020. The most significant advantages are durability, which helps overcome the barrier of huge storage space necessary for disposable insulin pens, and the ability to carry a 3–5-day supply. Meanwhile, reusable insulin pens are more accurate in meeting dose accuracy according to international standards (ISO-11608-1). They are equipped with additional features such as audible, visual, and tactile feedback during dose dialing to aid application and reduce the risk of human errors during handling. In addition, the newer reusable insulin pens have the advantage of adjusting a selected dose without losing insulin, as opposed to previous pens with one-directional dial constraints that made it impossible to dial "back" the dose.
Additionally, the process of resetting the pen after changing to a new cartridge in older reusable pens was quite tough, as the piston rod had to be re-wound to its starting point. On the other hand, the newest reusable pens allow the user to insert the piston rod back into the pen rather than turning it. Reusable pens may be less expensive than vials and syringes, in addition to the benefits listed above. Furthermore, these insulin delivery pens are environmentally benign and may have an advantage over disposable pens in contributing to less plastic waste. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
Geographical Analysis
North America region holds the largest market share in the global automated insulin delivery systems market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of the diabetic population, technological advancement in the devices, well-established healthcare facilities in the region, acquisition and collaboration by the market players are some of the factors due to which the market is expected to boost in the forecast period. For instance, According to the Centers for Disease Control (CDC), diabetes was the seventh leading cause of death in the United States. In 2018, an estimated 1.5 million new cases of diabetes were diagnosed among U.S. adults aged 18 years or older. In contrast, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes, and nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents.
Moreover, Abbott and Tandem Diabetes Care signed an agreement in June 2020 to create and market Abbott's continuous glucose monitoring (CGM) systems alongside Tandem's revolutionary insulin delivery systems to provide diabetes care solutions that address the gap in the market. Insulet also teamed with the other two businesses in February 2020 to advance diabetes management technology. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Competitive Landscape
Major key players in the automated insulin delivery systems market are Medtronic, Novo Nordisk, Insulet Corporation , Tandem Diabetes Care, Inc, Ypsomed AG, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Biocon, Bigfoot Biomedical, Inc. and sanofi-aventis U.S. LLC.
Medtronic Plc:
Overview:
Medtronic plc is an American-Irish registered medical device company primarily operating in the United States. It has an operational and executive headquarters in Fridley, Minnesota, in the US. Moreover, it develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes. It is operated in 140 countries and employs over 104,950 people.
ÂProduct Portfolio:
MyLab™9VET
MiniMed 670G system: The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user-selectable rates) and administration of insulin boluses (in user-selectable amounts) to manage type 1 diabetes mellitus in persons seven years of age and older.